Group 1: Investment Strategy - A formula for generating strong returns involves investing small amounts in top stocks regularly over long periods, with fractional shares being one method to apply this strategy [1] - Attractive corporations can be found at affordable prices, particularly in the healthcare sector [2] Group 2: Pfizer - Pfizer's shares have significantly declined due to reduced revenue and earnings post-coronavirus success, with a notable patent cliff approaching for Eliquis [4] - The company has improved its pipeline and received major approvals, which are expected to positively impact revenue over time [5] - Pfizer is engaged in cost-cutting efforts, planning to reduce expenses further through 2027 [5] - The company offers a strong dividend program, having increased payouts by 19.45% over the past five years, with a forward yield of 7.1% [6] - Pfizer's forward price-to-earnings ratio is 8.3, significantly below the healthcare industry average of 16.1, indicating it is reasonably valued [6] - While recovery may take time, it is considered a worthwhile investment for patient, income-seeking investors [7] Group 3: Exelixis - Exelixis specializes in oncology, with its top-selling product, Cabometyx, approved for various cancers, contributing positively to revenue and earnings [9] - The company won a patent litigation case, ensuring Cabometyx's generic version will not enter the market until early 2030, which is crucial for financial stability [10] - Cabometyx received a label expansion for treating pancreatic neuroendocrine tumors, maintaining a strong market share in renal cell carcinoma treatments [11] - Exelixis announced positive results for its next-gen cancer medicine, zanzalintinib, in a phase 3 study for metastatic colorectal cancer, addressing an unmet need [12] - With these developments, Exelixis's future appears promising, with shares currently priced at $44, suggesting potential for solid returns if held for five years or more [13]

Alongside more typical left-wing fare, like rent controls and free buses, Zohran Mamdani pitched a more novel idea: public grocery stores. But that won’t solve New York’s affordability problem https://t.co/tWwI35WYV7 ...

From @WSJopinion: Democrats can embrace the need to address the people’s angst about the economy and affordability, without embracing the socialism of Mamdani or the extremism of Trump, writes @Tom_Suozzi https://t.co/5cFOLhaRJI ...

Keeping our focus on Capitol Hill and Hakee Jeff still holding the floor. I want to bring in Josh Godheimer, Democratic Congressman from New Jersey who serves as vice chair to the House Problem Solvers Caucus. Congressman, just to be clear, do you see any way that this bill doesn't pass at this point.No, this thing is going to pass and the Republicans are going to own this debacle of a piece of legislation that's going to not only get more unpopular as people learn what's in this bill, but is going to criti ...

Buying a home in America's largest metros would require more than 30% of the median income. https://t.co/x1gjjAvTAV ...

Key Takeaways Teleflex completed its 760 million euro acquisition of BIOTRONIK's Vascular Intervention business. The deal expands TFX's interventional access line and supports resorbable scaffold tech development. The acquisition is expected to add $0.10 to TFX's adjusted EPS in year one, with a rising impact thereafter.Teleflex (TFX) recently completed its previously announced acquisition of the majority of BIOTRONIK SE & Co. KG’s Vascular Intervention business. The acquisition significantly expands the ...

Affordable housing isn't something the government will solve.. it's only something that can come from competition and innovation.@BOXABL offers stunning dwellings 🏡 that can be set up in just a few hours once on location.Starting at just $60k - https://t.co/XFb3XyiJfX https://t.co/cNQjE258gv ...

Zohran Mamdani has promised free buses as part of his ambitious campaign to make NYC more affordable. But that could come with transit trade-offs https://t.co/qqsgLfQNx9 ...

Um, we're going to run out of time, but before you go, I have a question for you. Talking about giveaways, um, here in New York City, a place where you also used to live and used to run Robin Hood, a great charity that's done enormous things for this city. What you think of the race, uh, for mayor here between Mamani now and Eric Adams.I think those are really realistically the only two choices on the table. Yeah. You know, it's it's fascinating because I I I have not followed uh the the race as closely or ...

Tesla could really use the affordable EV it's been promising, but the timeline keeps slipping. As recently as April, Tesla said it would begin production of its mysterious new "affordable" EVs in the first half of 2025. But the deadline came and went on Tuesday with no word, and Wednesday saw the automaker report its second consecutive year-over-year decline in deliveries.When Tesla announced similarly bad delivery numbers in April, an analyst told Business Insider it made making an affordable EV even more ...